

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



*(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)
(Stock Code: 01099)*

ANNOUNCEMENT PRINCIPAL UNAUDITED FINANCIAL DATA OF CNMDC FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2026

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement dated 22 October 2026 (the “**Announcement**”) issued by Sinopharm Group Co. Ltd. (the “**Company**”), in relation to the Company’s subsidiary China National Medical Device Co., Ltd. (中國醫療器械有限公司) (“**CNMDC**”)’s and its consolidated unaudited balance sheet, income statement and cash flow statement for the nine months ended 30 September 2026 (the “**Reporting Period**”).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of CNMDC for the Reporting Period as set out in the Announcement.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.*

PRINCIPAL CONSOLIDATED UNAUDITED FINANCIAL DATA OF CNMDC

Unit: Yuan
Currency: RMB

	Reporting Period	Same period of last year	Changes of this period over the same period of last year (%)
Revenue	55,262,083,638.59	54,693,011,286.36	1.04
Operating profit	855,655,519.02	962,113,681.56	-11.07
Total comprehensive income attributable to owners of the parent company	391,208,526.39	395,277,818.67	-1.03
Net cash flow arising from operating activities	-1,720,064,183.70	-4,128,048,873.08	58.33
	At the end of the Reporting Period	At the beginning of the Reporting Period	Changes of this period-end over the beginning of this period (%)
Total assets	61,415,657,228.72	57,302,220,888.25	7.18
Total equity attributable to owners of the parent company	8,604,990,143.99	8,300,052,155.36	3.67

By order of the Board
Sinopharm Group Co. Ltd.
Jin Bin
Chairman

Shanghai, the PRC
22 October 2026

As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Yang Binghua; the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.